Skip to main content
OpenTrials
Completed

NCT Number: NCT00691769

Expression of Fas Protein in Skin Biopsies of Participants With Scarring Alopecia

The purpose of this research study is to see if a specific protein that we are interested in is involved in scarring hair loss. If these proteins are involved, further genetic work may also better define the disease as well as future treatment options.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Central Centrifugal Scarring Alopecia Alopecia Connective Tissue Diseases Discoid Lupus Erythematosus Hair Diseases Hypotrichosis Lichen Planopilaris Lichen Planus Lichenoid Eruptions Lupus Erythematosus, Cutaneous Lupus Erythematosus, Discoid Pathological Conditions, Anatomical Pathological Conditions, Signs and Symptoms Skin Diseases Skin Diseases, Papulosquamous Skin and Connective Tissue Diseases

Age range

30 year and older

Sex eligibility

Female

Study type

Observational

Primary location

Wake Forest University Health Sciences Dermatology

Winston-Salem, North Carolina, 27157, United States

About this study

This is a single-center study, designed to evaluate the expression of Fas protein in skin biopsies of patients with scarring alopecia including fourteen patients with central centrifugal scarring alopecia (CCSA), three patients with lichen planopilaris (LP) and three patients with discoid lupus erythematosus (DLE). Skin biopsies of five healthy participants will be used as controls.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Participants ages 30 years or older with a biopsy- proven diagnosis of CCSA.
  • Undergone standard of care treatment for CCSA by a WFUSM Dermatologist
  • Women of child bearing age will be required to have a negative pregnancy test in order to participate in the study
  • Participants ages 30 years or older with a biopsy- proven diagnosis of LP.
  • Participants ages 30 years or older with a biopsy- proven diagnosis of DLE.
  • Healthy participants must be ages 30 years or older.

Exclusion criteria

  • Age less than 30 years of age.
  • Clinically evident bacterial or viral infection of the scalp.
  • Pregnant or nursing woman of child-bearing potential.
  • Participation in any other investigative research study involving study medication.
  • Inability to return for the biopsy visit.

Treatment and study plan

Primary outcomes

  1. To evaluate the expression of Fas protein in skin biopsies of participants with central centrifugal scarring alopecia (CCSA), lichen planopilaris (LP) and discoid lupus erythematosus (DLE) and in healthy controls.

    Time frame: 8 weeks

Secondary outcomes

  1. To evaluate the expression of Fas protein in skin biopsies of participants with central centrifugal scarring alopecia before and after treatment with intralesional and topical steroids.

    Time frame: 8 weeks

Sponsors and collaborators

Lead sponsor

Wake Forest University

Other

Registry information

Important dates

Study start
2006
Primary completion
2012
Study completion
2012
First posted
Jun 5, 2008
Registry last updated
Jul 6, 2018

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.